TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond Authors: Qitong Wu, Deeptashree Nandi, Dipali Sharma Published: 2024 ABSTRACT While most Tripartite motif (TRIM) family proteins are E3 ubiquitin ligases, some members have functions beyond the regulation of ubiquitination, impacting normal physiological processes and disease progression. TRIM29, an important member of the TRIM family, exerts a predominant influence on cancer growth, epithelial-to-mesenchymal transition, stemness and metastatic progression by directly potentiating multiple canonical oncogenic pathways. The cancer-promoting effect of TRIM29 is also evident in metabolic interventions and interference with the efficacy of cancer therapeutics. As expected for any key node in cancer, the expression of TRIM29 is tightly regulated by non-coding RNAs, epigenetic modulation, and post-translational regulation. A systematic discussion of how TRIM29 is regulated in cancer, its influences on cancer progression, and its impact on cancer therapeutics is presented in this review. We also explore the context-dependent alterations between TRIM29 function from oncogenic to tumor suppression. As TRIM29 is involved in multiple aspects of cancer progression, a better understanding of its biological impact in cancer may help improve prognosis and develop novel therapeutic combinations, leading to improved personalized cancer care. Introduction Post-translational modifications are essential for the regulation and biological function of most proteins; hence, they play an important role in normal physiological activities as well as disease progression. Ubiquitination is an important post-translational modification that modulates a large number of oncogenes and tumor suppressors and actively impacts cancer initiation, progression and metastasis [1]. The tripartite motif (TRIM) proteins are RING-type E3 ubiquitin ligases containing a B-box type 1, a B-box type 2, a RING, and three zinc-binding domains [2–4]. Based on their domain structure, they are further characterized into subfamilies I to XI [5]. Several members of TRIM family are known for their versatile range of biological functions, including autophagy [6, 7], regulation of RNA [8] and cell cycle [9], DNA damage responses [10], and immune-related activities [11–13]. Importantly, mutations and functional disruptions of TRIM proteins are linked to an array of pathological conditions, including viral infections, neurogenerative diseases, developmental abnormalities, and development of cancer [5, 14–16]. Elevated expression of TRIM8, TRIM24, TRIM28, and TRIM32 in malignant tumor tissues contribute to neoplastic transformations [17, 18]. TRIM24 [19, 20], TRIM25 [21] and TRIM68 [22] have been implicated in the progression of breast and prostate cancers via activation of nuclear receptors. Positive correlation between the expression of TRIM23 [23] and TRIM59 [24] and more advanced stage in colorectal cancer (CRC) has been observed indicating their role as potential biomarkers for CRC detection or prognosis. TRIM29 is an important member of the TRIM family whose elevated expression level is noted in several malignancies including lung, bladder, and pancreatic cancers, and correlates with worse prognosis. Early investigations on TRIM29 initiated from an autosomal genetic disease: ataxia-telangiectasia (AT) [25, 26]. Individuals with AT suffer from neurological, developmental, and immunological defects and are susceptible to cancer [26]. Cells from AT patients consistently exhibited radiosensitivity [25], which intrigued scientists to explore the rationale behind this phenomenon. Since TRIM29 can complement the ionizing radiation sensitivity of AT group D fibroblasts, it was isolated for further inquiries [26, 27]. This also granted the other commonly used name of TRIM29—Ataxia Telangiectasia Group D Complementing (ATDC) [27]. However, even as TRIM29 was postulated as a causal factor for AT, this idea was overthrown as another gene, ataxia-telangiectasia mutated (ATM) was found to be responsible for AT [28]. Nevertheless, ATM is involved in the expression of TRIM29 to influence hypoxic response in breast cancer [29], which will be discussed in later text. TRIM29 exhibits differential expression across the body organs. In the brain, TRIM29 can be found only in cerebral cortex [30]. TRIM29 expression is the highest in nasopharynx, followed by bronchus and lungs within the respiratory system. In the proximal digestive tract, TRIM29 is enriched in oral mucosa and esophagus but its expression is lower in the salivary gland, whereas in the gastrointestinal tract, TRIM29 is detected in the rectum only. In addition, TRIM29 can be found in the pancreas, the urinary bladder, and gender-specific tissues (proteinatlas.org). In addition to serving as an E3 ubiquitin ligase, TRIM29 plays a significant role in several biological functions pertaining to cancer growth and metastatic progression. Unlike many other oncogenic or tumor suppressor proteins, TRIM29 has not been found to be regulated by mutations, amplifications, or deletions across different cancer types. Yet, like most key regulatory proteins with important functional implications, TRIM29 expression is tightly regulated via an array of microRNAs (miRs) and long noncoding RNA (LncRNAs) as well as histone deacetylases and translational modifications (Fig. 1). miR-122 [31], miR-355-5p and miR-15b-5p [32] target TRIM29 in nasopharyngeal carcinoma, and lower expression of miR-122, miR-355-5p and miR-15b-5p, often observed in nasopharyngeal carcinoma, results in elevated TRIM29 expression and aggressive disease [32]. Several lncRNAs have also been implicated in TRIM29 regulation acting as sponges for miRs. LncRNA extracellular leucine-rich repeat and fibronectin type III domain containing 1-antisense RNA 1 (ELFN1-AS1) promotes the expression of TRIM29 in gastric cancer, and higher expression of ELFN1-AS1 and TRIM29 correlates with poor prognosis in gastric cancer patients [33]. Mechanistically, ELFN1-AS1 serves as a sponge for miR-211-3p, thereby augmenting expression of TRIM29, the target gene of miR-211-3p [33]. A similar phenomenon is also observed in non-small cell lung cancer and papillary thyroid carcinoma [34, 35]. LncRNA TP73-AS-1 targets miR-34a-5p competitively, thereby relieving its suppression on TRIM29, resulting in cisplatin resistance and increased tumor progression in non-small cell lung cancer [34]. In papillary thyroid carcinoma, higher levels of lncRNA LINC00324 leads to sponging of miR-195-5p and upregulation of TRIM29 aiding in increased cell proliferation and invasion potential [35]. A non-histone deacetylation event mediated by histone deacetylase 9 (HDAC9) at lysine116 on TRIM29 perturbs its binding to p53 and inhibits TRIM29-mediated increased cell proliferation [36]. The mammalian YTH domain family 1 (YTHDF1), identified as a potential TRIM29 mRNA-binding protein, promotes its translation in ovarian cancer cells [37]. The regulation of TRIM29 involves non-coding RNAs, epigenetic modifiers, and translational regulators, and its dysregulation contributes significantly to cancer progression and metastasis. In this review, we will discuss the multipartite mechanistic connections of TRIM29 with multiple cancer progression related signaling pathways; discuss how TRIM29 may modulate the cancer therapeutic regimens; and also, how it may function as a tumor suppressor gene in certain conditions.Fig. 1Upstream regulation of TRIM29. (miR = microRNA; ELFN-AS1 = extracellular leucine-rich repeat and fibronectin type III domain containing 1-antisense RNA 1; IKK\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\alpha\:$$\end{document}α = I\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\kappa\:$$\end{document}κB kinase \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\alpha\:$$\end{document}α) Upstream regulation of TRIM29. (miR = microRNA; ELFN-AS1 = extracellular leucine-rich repeat and fibronectin type III domain containing 1-antisense RNA 1; IKK\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\alpha\:$$\end{document}α = I\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\kappa\:$$\end{document}κB kinase \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\alpha\:$$\end{document}α) Multifaceted functional interactions of TRIM29 as it potentiates cancer progression Elevated expression of TRIM29 is observed in plasma cell myeloma [38], endometrial neoplasm [39], bladder cancer [40, 41], ovarian serous papillary tumors [42], and lung squamous cell carcinoma [43]. In many cancers, including gastric cancer [44] and pancreatic cancer [45], TRIM29 expression is positively correlated with tumor size, disease progression, and metastasis. In this section we discuss how TRIM29 orchestrates diverse oncogenic effects via modulating various tumor suppressors, oncogenes and pro-cancer signaling pathways. TRIM29 as a modulator of tumor suppressor p53 As the guardian of the genome, p53 can exert profound influence on tumor suppression [46, 47] but it is mutated or functionally attenuated to some degree in most human cancers [48, 49]. TRIM29 regulates p53 function, wherein TRIM29 facilitates cytoplasmic sequestration of p53 leading to the downregulation of p53-regulated genes, p21 and NOXA [50]. Interaction between TRIM29 and p53 requires N terminus of TRIM29 and is regulated by the acetylation of lysine 116 on TRIM29 [50]. Additionally, TRIM29 influences p53-related gene expression by suppressing Tip60 [51], an essential acetyltransferase for p53-mediated apoptosis and cell growth arrest [52]. A negative relation has been reported between TRIM29 and Tip60, and overexpression of TRIM29 prevents the translocation of Tip60 from the cytosol to the nucleus [51]. While p53 is an important tumor suppressor, mutant p53 has been shown to confer chemoresistance in patients with colorectal cancer [50, 53–56], via upregulation of MDR1 [57, 58]. Interestingly, while TRIM29-mediated cytoplasmic sequestration of p53 has a tumor-promoting effect [50], TRIM29-directed sequestration of the mutant p53 inhibits mutant p53-induced expression of MDR1, thereby sensitizing colon cancer cells to chemotherapy [59]. To sum up, the intricate interactions between p53 and TRIM29 highlight its pivotal role in promoting cancer progression as well as modulating the response to treatment (Fig. 2).Fig. 2TRIM29 regulates p53. (HDAC9 = histone deacetylase 9; Ac = acetylation) TRIM29 regulates p53. (HDAC9 = histone deacetylase 9; Ac = acetylation) NF-κB alteration by TRIM29 supports cancer growth Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) family is composed of five master transcription factors (RelA/p65, RelB, c-Rel, NF-κB1/p105, NF-κB2/p100) that can regulate transcription of responsive genes by forming various homodimers and heterodimers [60], and influence multiple physiological events, including proliferation, differentiation, cell adhesion, senescence, survival, and autophagy [61–64]. It is interesting to note that TRIM29 regulates NF-κB in non-small cell lung cancer cells and bladder cancer cells [65, 66]. TRIM29 increases NF-κB transcriptional activity leading to the upregulation of cyclin D1 and c-Myc expression, and supports growth and proliferation of non-small cell lung cancer cells. In accordance, pro-lung cancer effects of TRIM29 are inhibited with NF-κB inhibitor [65]. Similarly, overexpression of TRIM29 in bladder cancer cells results in upregulation of Bcl-2, cyclin D1, and cyclin E [66], that mediate cell survival and proliferation, and are downstream targets of the NF-κB signaling pathway [67]. Silencing TRIM29 or treatment with NF-κB inhibitor decreases growth of bladder cancer cells [66]. Moreover, inhibition of protein kinase C (PKC), an upstream effector of the NF-κB pathway [68], prevents TRIM29-induced activation of NF-κB, suggesting that the oncogenic functions of TRIM29 are partly ascribed to PKC-related activation of NF-κB signaling pathway [66]. Connection between NF-κB and TRIM29 in cancer presents an important axis whose functional modulation can help with improved treatment regimens. TRIM29 augments the oncogenic PI3K/AKT/mTOR signaling pathways Components of PI3K/AKT/mTOR pathway play important role in various aspects of cancer growth and progression. Enhanced TRIM29 expression in thyroid cancer associates with higher growth and metastasis, poor overall survival, and reduced response to therapy while TRIM29 knockout leads to increased apoptosis, diminished migratory potential, and sensitization to chemotherapy via suppression of the PI3K/AKT signaling pathway [69]. Of note, TRIM29 mediated PI3K/AKT activation is crucial for its impact on thyroid cancer progression [69]. A recent study revealed that TRIM29 promotes cellular proliferation and metastasis in colorectal cancer by indirectly influencing the PI3K/AKT signaling pathway [70], where circular RNA circIL4R activates the PI3K/AKT pathway to confer enhanced aggressive behavior [70]. Moreover, circIL4R increases the expression of TRIM29 by acting as a sponge for miR-761, which negatively regulates TRIM29 [70]. Noting that circIL4R is also related to the PI3K/AKT pathway, it is reasonable to draw the connection between circIL4R, TRIM29, and the PI3K/AKT activity [70]. In recent years, the pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase (PHLPP) family has been recognized as a key modulator that decreases cell survival via suppression of the AKT signaling cascade in multiple cancers [71–73]. Interestingly, TRIM29 overexpression significantly promotes the ubiquitin-mediated degradation of PHLPP1 [70] hence relieving the PHLPP-mediated AKT suppression. TRIM29 overexpression can also suppress PTEN levels in nasopharyngeal carcinoma, which subsequently activates the PI3K/AKT pathway [32]. Augmented migratory potential by TRIM29 overexpression is reversed by the addition of an mTOR inhibitor or an AKT inhibitor [32, 74]. Moreover, TRIM29 overexpression leading to PTEN silencing in nasopharyngeal cancer cells rescues PI3K/AKT signaling activity, indicating that TRIM29 strengthens the aggressiveness of nasopharyngeal cancer cells via suppressing PTEN to promote the PI3K/AKT signaling pathway [32]. The mechanism whereby TRIM29 suppresses PTEN has been delineated in bladder cancer [41] implicating epigenetic modifier DNMT3A. Essentially, MYC expression increases upon TRIM29 overexpression, which leads to reduced miR-29 level, thus increasing the availability of DNMT3A, resulting in significant downregulation of PTEN [41, 75]. In summary, TRIM29 aids the aggressiveness of cancer via activation of the oncogenic PI3K/AKT/mTOR pathway. Unraveling how TRIM29 modulates such pathways provides insights into potential therapeutic strategies for targeted treatment in cancer. TRIM29 enhances KRAS-induced tumorigenesis One of the most famous and often mutated oncogenes in cancer is Kirsten rat sarcoma viral oncogene homologue (KRAS) [76, 77]. As a GTPase transductor protein, KRAS’ abilities extend to regulation of cell cycle, apoptosis, and senescence [78]. Wild-type KRAS has been recognized as a tumor suppressor [77]. In cancer, it is often lost, or mutated, and gains oncogenic features [78]. Importantly, oncogenic KRAS upregulates TRIM29 in a subpopulation of pancreatic intraepithelial neoplasia cells [79]. Further, TRIM29 expression is required for the transition from acinar-to-ductal metaplasia to pancreatic intraepithelial neoplasia in the context of oncogenic KRAS; and this effect is mediated via TRIM29-induced β-catenin activation [80]. Some studies have suggested that Sox9 is the key transcription factor that drives acinar-to-ductal metaplasia to pancreatic intraepithelial neoplasia transition, and the development of pancreatic adenocarcinoma [81–83], and TRIM29 supports this transition by stimulating Sox9 [80] through β-catenin signaling pathway [84]. In fact, in a pancreatic adenocarcinoma mice model bearing oncogenic KRAS, ectopic expression of TRIM29 results in a significant enhancement in tumor progression and metastatic potential [79]. As expected, TRIM29-induced activation of β-catenin signaling and more pronounced epithelial-to-mesenchymal transition is evident in this model [79]. It is interesting to note that mutations of tumor suppressors such as p53, p16, and Smad4 are often observed in pancreatic intraepithelial neoplasia [85] but the aggressive phenotype in the TRIM29-overexpressing mice model with oncogenic KRAS is independent of the suppression mediated by these tumor suppressors [79], highlighting the effect of TRIM29 in refining the aggressiveness in PDAC. At this point, how TRIM29 is interfering with oncogenic KRAS is only evident in pancreatic adenocarcinoma. Considering the complexity of cancer, deciphering such interaction is important for the optimization of cancer treatment. TRIM29 supports the pro-oncogenic signaling cascades to boost cancer progression Wnt/β-catenin cascade plays a crucial role in maintaining physiological homeostasis as well as disease progression [86]. β-catenin is tightly regulated by several ligands as well as the ‘destruction complex’ consisting of multiple proteins including the casein kinase 1 (CK1), the Ser/Thr kinases glycogen synthase kinase 2 (GSK3), the adenomatous polyposis coli (APC) protein, E3-ubiquitin ligase β-TrCP, the β-catenin protein, and Axin as the scaffold protein [87–89]. TRIM29 directly binds to Axin and GSK3β disrupting the ‘destruction complex’ hence inhibiting β-catenin phosphorylation and subsequent ubiquitination and degradation [45]. Elevated levels of TRIM29 in pancreatic ductal carcinoma leads to increased β-catenin signaling and expression of β-catenin/TCF target genes ensuing enhanced tumor growth [45]. Additionally, Dvl is known to stabilize β-catenin by interacting with Axin and GSK3β, and inhibiting phosphorylation of β-catenin [90–93], thereby contributing to the increased accumulation of nuclear β-catenin. As demonstrated by Wang and colleagues, TRIM29 overexpression leads to upregulation of Dvl2, and this axis is indispensable in enhancing the β-catenin/TCF activity [45]. A recent study reported that direct inhibition of Dvl2 in pancreatic ductal carcinoma results in reduced tumorgenicity in vitro and in vivo [94]. Nonetheless, additional studies are needed to decipher whether inhibiting Dvl2 or TRIM29 would be more effective in a clinical setting to treat pancreatic ductal carcinoma patients. TRIM29-induced activation of β-catenin is also evident in pancreatic intraepithelial neoplasia, a well-known precursor of pancreatic ductal carcinoma [95]. CD44, a key trigger for epithelial-mesenchymal transition, is also downstream of the TRIM29-induced β-catenin signaling pathway in pancreatic cancer [79]. Here, miR-449a targets TRIM29 directly leading to decreased β-catenin/TCF-dependent transcriptional activity and decreased mRNA expression of CD44 [96]. Moreover, several studies have reported that overexpression of TRIM29 in gastric cancer is related to poor prognosis [44, 97, 98]. Qiu and colleagues revealed that knocking down TRIM29 triggers cell cycle arrest and promotes apoptosis, likely due to suppression of the Wnt/β-catenin signaling pathway in gastric cancer [99]. Similarly, TRIM29 upregulation is observed in cervical cancer tissues, and its silencing results in decreased growth, colony-forming ability, and migratory potential in cervical cancer cells through decreased β-catenin activation [100]. Importantly, c-Myc, a downstream target of β-catenin, is also suppressed upon TRIM29 silencing implicating that TRIM29 might stabilize β-catenin [100, 101]. Indeed, Xu and colleagues discovered that si-TRIM29 also leads to a significant increase in GSK3β, suggesting that TRIM29 promotes the aggressiveness of cervical cancer by activating epithelial-mesenchymal transition via activation of the Wnt/β-catenin signaling pathway [100]. Moreover, it has been reported that miR-621 diminishes the aggressiveness of bladder cancer by targeting TRIM29, which results in decreased Wnt/β-catenin signaling [102]. Together, TRIM29 mediates progression of several cancer types through the activation of Wnt/β-catenin signaling. The Hippo/YAP/TAZ pathway is another important signaling cascade involving multiple upstream effector molecules culminating in the activation/inhibition of responsive gene expression and cancer cell modulation [103–105]. A recent study demonstrated the connection between TRIM29 and YAP1 in pancreatic cancer cells where TRIM29 directly binds to YAP1 reducing its ubiquitination and increasing its half-life. Cancer promoting effects of TRIM29 in pancreatic cancer involved YAP1 overexpression as YAP1 silencing partially abolishes TRIM29’s oncogenic effects [106]. Association between TRIM29 and stem-cell-like characteristics in cancer A higher population of cancer stem cells (CSCs) in tumors has been recognized as an indicator of unfavorable outcomes [107, 108] as CSCs have a profound impact on tumor progression and metastasis, and especially recurrence [109]. The connection between CSC-like behavior and TRIM29 was first drawn in 2013 [110] using a human-in-mouse orthotopic model in head and neck squamous cell carcinoma where TRIM29 overexpression associated with EMT and stemness along with CAV-1, TLR-4 (Toll-like receptor 4), MMP-7 (matrix metalloproteinase 7), ALDH1A3, and OCT-4 [110]. In pancreatic ductal adenocarcinoma, TRIM29 participates in the regulation of CSCs via mediating interferon-stimulated gene 15 (ISG15) [111] which promotes ERK1/2 phosphorylation, thereby enhancing CSC characteristics [112]. Recently, evidences from both in vitro and in vivo models revealed that stable knockout of TRIM29 in pancreatic ductal adenocarcinoma results in reduced CSC phenotypes [111]. Further inquiries disclosed that silencing TRIM29 leads to increased calpain 3 (CAPN3), which, in turn, stimulates CAPN3-mediated processing of ISG15, resulting in a decrease in ISG15 expression [111]. Zhao et al. reported an upregulation of TRIM29 expression in mice treated with human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) along with enhanced phosphorylation of ERK1/2 and AKT [113]. They also demonstrated a sharp decline in the anti-apoptotic effects of hUC-MSC-CM (hUC-MSCs derived conditional medium) upon silencing of TRIM29 [113], implying the role of TRIM29 in resisting apoptosis. On the other hand, PP2A (protein phosphatase-2 A) is a holoenzyme that serves as a tumor suppressor in most cancer types [114–117]. Existing studies suggested that overexpressing PP2A reduces undifferentiated human embryonic stem cells [118]. Moreover, as directed by PR61α, PP2A promotes the degradation of c-MYC [119], thus contributing to a decrease in stem-like behaviors [120]. SET is an endogenous inhibitor of PP2A, which disrupts PP2A function by direct interaction [121]. Moreover, SETBP1 (SET binding protein 1) binds to SET, thereby preventing proteasome degradation of SET, rendering substantial inhibition of PP2A—this often culminates in adverse patient outcomes [122]. In ovarian cancer, vascular endothelial zinc finger 1 (VEZF1) is found to be a transcriptional activator of SETBP1 [123]. Qiao and colleagues reported that TRIM29 promotes VEZF1 expression via interaction with the 3’UTR region at its mRNA [123]. At 3’UTR, gene expression is often regulated by interaction with RNA binding proteins (RBPs) [124]. In this case, TRIM29 specifically recruits BICC1 (BicC Family RNA Binding Protein 1) to the 3’UTR of VEZF1 mRNA to promote translation [123]. Subsequently, VEZF1 activates the SETBP1/SET/PP2A axis, thereby encouraging the CSC phenotype in ovarian cancer [123]. Overall, TRIM29 has positive influence on governing CSC characteristics across different malignancies. Understanding these interactions would provide valuable insights in development of therapeutics for tumor progression and metastasis. TRIM29 has diverse functions in carcinoma induction In nasopharyngeal carcinoma patient samples, hypomethylation results in enrichment of TRIM29 that is related to poor prognosis [125]. TRIM29 directly binds to voltage-dependent anion-selective channel 1 (VDAC1) to induce mitophagy, prevent cellular senescence and promote cancer cell proliferation [125]. A positive relation has been observed between TRIM29 and fibronectin1 (FN1) among papillary thyroid cancer tissue samples and silencing TRIM29 leads to ameliorated migration and invasion in PTC via downregulation of FN1 [126]. In pancreatic cancer, TRIM29 is positively related with AK4 (adenylate kinase isoform 4) [127]. AK4 is a member of the adenylate kinase family that maintains nucleotide homeostasis [128]. It is mainly found in the mitochondria, where it functions as a stress-responsive protein by binding to mitochondrial ADP/ATP translocase thus contributing to survival [129, 130]. AK4 is associated with poor prognosis when expressed at a high level among patients with pancreatic cancer [127]. Unsurprisingly, supplementing AK4 can reverse the inhibitory effect of silencing TRIM29 in the aggressiveness of pancreatic cancer [127]. TRIM29 inhibition not only reduces glycolysis but also causes elevation of mitochondrial oxidative phosphorylation by downregulating AK4 [127]. Even though it is unclear how TRIM29 impacts glycolysis in pancreatic cancer, this area was investigated in colorectal cancer. Increased glycolysis is associated with a more advanced stage of colorectal cancer [131] and the development of chemoresistance [132]. As disclosed by Han and colleagues, TRIM29 promotes ubiquitin-mediated degradation of PKM1 (pyruvate kinase M1) [133], thereby encouraging colorectal cancer cells to perform glycolysis instead of oxidative phosphorylation [133]. Further, as an important mechanism in cellular homeostasis, autophagy can be pro-death or pro-survival [134]. Activation of cytoprotective autophagy is a common strategy in cancer to promote metastasis, recurrence, and resistance to therapy [135, 136]. In lung squamous cell carcinoma, TRIM29 is reported to promote metastasis and proliferation by evoking cytoprotective autophagy [137]. As demonstrated by Xu and colleagues, TRIM29 binds to the promoter of Beclin-1, a central regulator of autophagy [138], thereby promoting autophagy and metastasis in lung squamous cell carcinoma [137]. TRIM29 plays an important function in host metabolic regulation and homeostasis, which can potentially contribute to cancer progression. Overall, TRIM29 acts in conjunction with several important oncogenic nodes to transform multiple functional networks that modify the host physiology (Fig. 3).Fig. 3TRIM29 stimulates a number of oncologic pathways. (YAP = Yes-associated protein; PKC = protein kinase C; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells; KRT5 = keratin 5; mTOR = the mammalian target of rapamycin; PTEN = phosphatase and tension homolog; PHLPP1 = pleckstrin homology domain leucine-rich protein phosphatase; miR = microRNA; DNMT3A = DNA (cytosine5)-methyltransferase 3 A; DVL = Disshevelled; EMT = epithelial-mesenchymal transition; KRAS = Kirsten rat sarcoma viral oncogene homologue; ADM = acinar-to-ductal metaplasia; PanIN = pancreatic intraepithelial neoplasia; PDAC = pancreatic adenocarcinoma) TRIM29 stimulates a number of oncologic pathways. (YAP = Yes-associated protein; PKC = protein kinase C; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells; KRT5 = keratin 5; mTOR = the mammalian target of rapamycin; PTEN = phosphatase and tension homolog; PHLPP1 = pleckstrin homology domain leucine-rich protein phosphatase; miR = microRNA; DNMT3A = DNA (cytosine5)-methyltransferase 3 A; DVL = Disshevelled; EMT = epithelial-mesenchymal transition; KRAS = Kirsten rat sarcoma viral oncogene homologue; ADM = acinar-to-ductal metaplasia; PanIN = pancreatic intraepithelial neoplasia; PDAC = pancreatic adenocarcinoma) TRIM29 influences treatment outcomes in cancer While various targeted treatment regimens are available for different cancers, chemotherapy and radiotherapy still form the backbone of cancer treatment. Hence, poor response to chemotherapy or radiotherapy poses a predominant limitation of contemporary anticancer therapeutic modules. Considering the quintessential involvement of TRIM29 in determining oncogenic outcomes, understanding the implications of TRIM29 in regulating the efficacy of tumor suppressive strategies is an imperative area of research focus [139, 140]. Radiotherapy Radiotherapy, a prevalent anticancer therapeutic strategy, is a local ionizing radiation (IR) treatment that is applied to impart tumor shrinkage or clearance of residual cancer cells [141–143]. In the past two decades, the survival rate of cancer patients who underwent radiotherapy has increased by 50% [143, 144]. But resistance to radiotherapy has emerged as an unavoidable concern. The development of radio-resistance is associated with the efficiency of DNA repair in cancer cells [141]. After cells undergo IR, double-strand DNA breaks (DSBs) occur in an attempt to halt the cell cycle and repair the genomic damage. If the damaged DNA is not repaired in a timely and efficient manner, apoptosis takes place to avoid the generation of daughter cells with incomplete or damaged genome [145, 146]. Therefore, cancer cells that are proficient in DSB repair are more likely to be resistant to IR therapy [141]. The Simeone lab demonstrated that expression of TRIM29 in pancreatic cancer is positively associated with radio-resistance [147]. Mechanistically, as mediated by ATM, TRIM29 can be phosphorylated by MAP kinase-activated protein kinase 2 (MAPKAPK2) at S550, located at the C terminus of TRIM29 [147, 148]. Subsequently, phosphorylated TRIM29 interacts with RNF8 at its RING domain [149], resulting in an accelerated DNA repair, accompanied by increased colony forming ability, improved DSB repair kinetics, and faster resolution of DNA repair foci [149]. It was previously believed that TRIM29 stays in the DNA damage foci along with γH2AX and ATM, resulting in a radioprotective effect [147]. Further research showed that TRIM29 binds to the chromatin and facilitates RNF8-mediated ubiquitination of γH2AX and phosphorylation of 53BP1 [149]. Interaction of TRIM29 and RNF8 also promotes IR-induced DNA repair foci resolution, contributing to the radioprotective effect [149]. Importantly, even though TRIM29S550A does not confer radio-resistance in pancreatic cancer cells, TRIM29S550A is proficient in promoting cell growth, indicating that the radioprotective role of TRIM29 is independent of its influence on proliferation [147]. Chemotherapy Although chemotherapy is the mainstay for treating cancer [150–152], over 80% of cancer-related deaths are attributed to chemoresistance [139, 153, 154], highlighting the crucial need of understanding its underlying molecular mechanism. Recently, functional chromosomal rearrangements have been identified in the cancer genome. Functional gene fusions may code for oncogenic proteins that aid the progression of cancer [155–158]. A novel gene fusion, SPON1-TRIM29, was first discovered in tumor samples from two patients with high-grade serous ovarian cancer (HGSC) [159]. Gain- and loss-of-function experiments in cisplatin-resistant ovarian cancer cells confirmed that SPON1-TRIM29 is positively associated with proliferation [159]. Xenograft model in mice demonstrated that SPON1-TRIM29 markedly promotes tumor progression, though precisely how the expression of SPON1-TRIM29 differs upon the use of chemotherapeutics in mice is not yet clear [159]. It is suspected that the SPON1-TRIM29 rises from genome instability related to R342X mutation at mRNA of TP53 [159, 160]. The fusion protein, SPON-TRIM29 consists of the N-terminal signal sequence of SPON1 and the C-terminal region of TRIM29 [159]. Similar to TRIM29, the effect of SPON1 can also be tumor-suppressing or tumor-promoting depending on the context [161–163]. Since the C-terminal of TRIM29 is retained in this gene fusion product, SPON1-TRIM29 may also interact with RNF8 to enhance DNA repair efficiency in cancer cells as a mechanism of chemoresistance [159]. Similarly, suppressing TRIM29 has been shown to sensitize them to cisplatin in non-small cell lung cancer [34] and lung squamous cell carcinoma [164]. TRIM29 has been reported to confer cisplatin resistance by activating the NF-κB signaling pathway, leading to upregulation of Bcl-2, which prevents apoptosis [66]. Further investigation is needed to explore if additional pathways are involved in this chemoresistance exerted by TRIM29. We have mentioned earlier that TRIM29 sequesters wild-type or mutant p53 to the cytoplasm [50, 59]. Since mutant p53 may promote development of chemoresistance [56, 165], while wildtype p53 can be key to induce cytotoxicity for chemotherapy [166–168], TRIM29 can be a critical player in determining the therapeutic outcomes of combination treatment involving p53 modulation such as APR-246 [48]. Collectively, TRIM29 contributes to therapeutic resistance via enhancement of DNA repair and p53 modulation. These findings indicate the importance of TRIM29 as a therapeutic target in cancer patients with recurrent diseases (Fig. 4).Fig. 4TRIM29 promotes therapeutic resistance. (RNF8 = ring finger protein 8; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells) TRIM29 promotes therapeutic resistance. (RNF8 = ring finger protein 8; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells) TRIM29 may act as a tumor suppressing agent in a context-dependent manner Despite multiple evidences supporting the involvement of TRIM29 in mediating carcinogenesis, there exist conflicting studies that advocate for TRIM29’s tumor suppressor role (Fig. 5). TRIM29 has been recognized as a tumor suppressor in breast cancer, and it is often hypermethylated and thus downregulated [169]. In mammary epithelial cell line, MCF10A, silencing TRIM29 leads to transformation to pre-neoplastic phenotypes [170]; while overexpressing TRIM29 in hormone-receptor positive breast cancer cell line diminishes its aggressiveness via antagonizing the proliferative effects of estrogen (E2) [170]. In accordance with this, introduction of TRIM29 in hormone-receptor positive breast cancer cells decreases the binding of estrogen receptor (ER) to estrogen response elements leading to inhibition of ER-responsive genes [170]. TRIM29 also suppresses breast cancer independent of alterations in E2:ER signaling. In a systematic investigation in taxifolin-mediated suppression of cancer growth in murine breast cancer model, upregulation of TRIM29 was evident after treatment of taxifolin [171]. Importantly, breast cancer with a lower proliferation index has a higher mRNA expression of TRIM29 [171, 172], implying that TRIM29 has a negative impact on tumor growth.Fig. 5TRIM29 may act as tumor suppressor. (ZNF750 = Zinc Finger Protein 750; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells; ATM = Ataxia telangiectasia mutated; EMT = epithelial-mesenchymal transition; ER = estrogen receptor) TRIM29 may act as tumor suppressor. (ZNF750 = Zinc Finger Protein 750; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells; ATM = Ataxia telangiectasia mutated; EMT = epithelial-mesenchymal transition; ER = estrogen receptor) Contrary to the observations of a positive influence of TRIM29 on EMT in cervical cancer [100] and pancreatic cancer [45], some studies suggest that TRIM29 functions as a negative regulator of EMT [169, 173]. As demonstrated by Ai and colleagues, silencing TRIM29 in breast cancer cell lines results in enhanced migratory potential and proliferation due to activation of EMT [169], and a marked increase of TWIST1, a key transcription factor that drives EMT. In an epigenetic study on TWIST-driven EMT, expression of TWIST1 is induced by treatment of 4-hydroxy tamoxifen in human mammary epithelial cells (HMECs) [173]. TWIST-driven EMT results in changes in chromatin structure and accessibility, which, in turn, leads to TRIM29 downregulation [173]. In HMECs, inhibition of TRIM29 increases mesenchymal markers N-cadherin and Vimentin [173]. Interestingly, silencing TRIM29 in non-malignant breast epithelial cells and luminal breast cancer cells results in upregulation of N-cadherin and Vimentin with a decrease in E-cadherin, accompanied by a drastic increase of TWIST1 [169]. Such inconsistency may be due to context-dependent molecular interaction pertaining to TRIM29, which demands further investigation [173]. Moreover, Gene Enrichment and Functional Annotation Analysis has been performed in genes that are differentially expressed upon knockdown of TRIM29 in HMECs. Several clusters of genes have been identified, and they are involved in cell death, differentiation, chemotaxis, inflammation, development of the epidermis, and cell junctions [173], indicating that TRIM29 is potentially important in regulating cellular functions in many aspects. Furthermore, TRIM29 participates in hypoxic response of breast cancer cells, and it is dependent on the tumor-suppressing function of ATM [29]. Reportedly, TRIM29 expression can be transcriptionally stimulated by ATM and HIF1α during hypoxia in breast cancer cell lines, which diminishes TWIST1 [29]. In esophageal squamous cell carcinoma, Zinc Finger Protein 750 (ZNF750) has been recognized as a prognostic indicator as its expression is significantly associated with better survival and decreased chance of metastasis [174]. As an important tumor suppressor in esophageal cancer, mutations, or suppression of ZNF750 are prevalent in esophageal squamous cell carcinoma [175–178]. Of note, the downregulation of TRIM29 is also observed in esophageal squamous cell carcinoma, and TRIM29 is positively related to the expression ZNF750 [179]. Like ZNF750 [177], TRIM29 expression is negatively associated with SNAI1 [179], an important transcriptional regulator in EMT [180]. Further investigation suggested that an elevated TRIM29 expression indicates a positive prognosis in patients with esophageal cancer, but TRIM29 is often downregulated due to hypermethylation at its promoter [179]. Additionally, TRIM29 inhibits migration and proliferation in esophageal squamous cell carcinoma in vitro and in vivo via induction of ZNF750, thus resulting in the modulation of proteins involved in epidermal differentiation and keratinization, which has deeper implications in EMT [179]. Of note, TRIM29 expression is negatively related to p-STAT3. While silencing TRIM29 promotes invasion and EMT markers in esophageal squamous cell carcinoma cells, this effect is abolished by inhibition of the IL6-STAT3 pathway [179]. Hence, by disrupting the STAT3 signaling pathway, TRIM29 functions as a tumor suppressor that upregulates ZNF750 in esophageal squamous cell carcinoma [179]. Furthermore, like esophageal squamous cell carcinoma, TRIM29 is not only hypermethylated and suppressed in squamous cell carcinoma, in vitro knockdown of TRIM29 also enhances cell growth and invasion in squamous cell carcinoma [179]. As disclosed by Yanagi and colleagues, silencing TRIM29 in squamous cell carcinoma increases metastatic behavior of cells where alteration of keratin distribution may play an important role [181]. Moreover, TRIM29 is reported to facilitate the proliferation of lung cancer cells by stimulating the NF-κB signaling pathway [65]. TRIM29 aids in growth of pancreatic cancer [50], gastric cancer [99], cervical cancer [100], and bladder cancer [102] by activating the β-catenin signaling pathway. On the contrary, Xu and colleagues reported that silencing TRIM29 in hepatocellular carcinoma enhances cell growth and migratory potential via activation of the Wnt/β-catenin signaling pathway, as evident in luciferase reporter assay [182]. This paradox is not uncommon in cancer [183, 184], possibly ascribed to the complexity of cancer and genetic variation [182]. TRIM29 and immune response Emerging research has shown the potential of many TRIM proteins in regulating the innate immune response (15), but there are not many existing studies that connect TRIM29 directly to cancer immunology and/or immunotherapy. TRIM29 was recognized as an important negative regulator of the canonical cGAS–STING–TBK1–IRF3 immune response by targeting STING for ubiquitin-assisted degradation [185–187]. Importantly, Cho et al. discovered SB24011, an inhibitor that specifically hinders the STING-TRIM29 interaction [188]. Combined treatment of SB24011 and anti-PD-1 resulted in a significant inhibition in tumor growth, suggesting the involvement of TRIM29 in dictating anti-PD-1 therapeutic response [188]. However, cGAS-STING signaling pathway may be foe or friend in cancer progression. It was previously described that down-regulation of STING resulted in decreased immune infiltration, which exacerbated tumor progression in skin and pancreatic cancer [189, 190]. Indeed, STING signaling pathway activates TBK1, which, in turn, inhibits Iκβα, resulting in NF-κB activation [191], and subsequent stimulation of NF-κB-dependent antitumor immunity [192]. Since TRIM29 can promote degradation of STING, it may play a role to suppress TBK1 activity, and, thereby, NF-κB. In contrast, as mentioned in previous text, TRIM29 stimulates NF-κB signaling via activation of PKC, thereby promoting aggression and cisplatin resistance. However, cancer therapeutics like cisplatin often elicit genomic stress and DNA damage. Such stressors often lead to activation of cGAS–STING signaling pathway to mitigate the stress. More recently, Jiang et al. demonstrated TRIM29 to potentiate the antitumor T-cell response and enhance the tumor suppressive effects of PD-1 therapy in gastric cancer, following ubiquitin-mediated degradation of IGF2BP1. TRIM29 expression was correlated with overall survival and infiltration of CD8 + T cells in gastric cancer patients [193]. However, it is unclear how these players are involved in cancer progression, prevention, treatment outcome, and immune regulation, which demands further investigation. Conclusion In conclusion, TRIM29’s role in cancer is multifaceted and intricate, with evidences supporting its function as a tumor suppressor or a cancer promoter. To support its oncogenic functions in cancer, TRIM29 has the leverage to activate the NF-κB pathway in lung cancer [65], bladder cancer [66], and colorectal cancer [68]. However, STAT3 can be downstream of NF-κB [194], and TRIM29 can suppress STAT3 in esophageal cancer [182] thus exhibiting tumor suppressing function. In Wnt/β-catenin pathway, similar paradox is also evident, since TRIM29 is positively related to this pathway in pancreatic cancer [45, 79, 96], gastric cancer [99], and bladder cancer [102], but TRIM29 downregulates the Wnt/β-catenin pathway in liver cancer [182]. Regarding EMT regulation, even though TRIM29 promotes EMT in colorectal cancer [195] and thyroid cancer [126], it suppresses EMT in esophageal cancer [128] and breast cancer [169]. Despite the tumor suppressor roles, TRIM29’s oncogenic functions seem more prominent in aiding cancer initiation, growth and metastatic progression as it augments the PI3K/AKT/mTOR pathway in thyroid cancer [69], colorectal cancer [70], nasopharyngeal cancer [32] and bladder cancer [41]; promotes CSC-characteristics in pancreatic cancer [111] and ovarian cancer [123]; suppresses p53 in colorectal cancer [50, 51]; promotes KRAS [79, 80] and modulates HIPPO/YAP in pancreatic cancer [106]; and contributes to cancer-supporting metabolic alterations in colorectal cancer [134], pancreatic cancer [127], lung cancer [137] and nasopharyngeal cancer [125]. TRIM29’s involvement in oncogenic pathways is summarized in Table 1. The intricate interplay between TRIM29 and various signaling pathways underscores its role in cancer (Fig. 6). Since TRIM29 may be tumor suppressing or enhancing cancer progression depending on the context, it can be a pivotal target when formulating personalized treatment for cancer patients. A major hindrance in including TRIM29 in cancer treatment at present is the lack of potent inhibitors or activators of TRIM29, hence, there is a dire need for the development of TRIM29 modulators which can be included in the combination regimens further finetuning the strategies based on the tumor characteristics. Table 1TRIM29 and its association with various pathways in cancerContextRolePathwayCitationMechanismregulation of p53colorectal canceroncogenicp53[50, 59]sequesters p53 at cytosolcolorectal canceroncogenicp53[51]inhibits Tip60NF-κB signaling pathwaylung canceroncogenicNF-κB[65]?bladder canceroncogenicNF-κB[66]activates PKCPI3K/AKT/mTORthyroid canceroncogenicPI3K/AKT/mTOR[69]?colorectal canceroncogenicPI3K/AKT/mTOR[70]suppresses PHLPP1 via ubiquitinationnasopharyngeal canceroncogenicPI3K/AKT/mTOR[32]suppresses PTENnasopharyngeal canceroncogenicPI3K/AKT/mTOR[31]may have relation with miR-122bladder canceroncogenicPI3K/AKT/mTOR[41]by inducing MYC, DNMT3A activation leads to suppression of PTENoncogenic KRASpancreatic canceroncogeniconcogenic KRAS[79, 80]promotes PanIN and stimulates Wnt/β-cateninHIPPOpancreatic canceroncogenicHIPPO[106]inhibits ubiquitination of YAP1Wnt/β-catenin and EMTpancreatic canceroncogenicWnt/β-catenin[45]disrupts destruction complex via DVL2pancreatic canceroncogenicWnt/β-catenin[79]in the presence of oncogenic KRAS, stimulates Wnt/β-cateninpancreatic canceroncogenicWnt/β-catenin[96]miR-449a suppresses both TRIM29 and β-cateningastric canceroncogenicWnt/β-catenin[99]may have relation with miR-185cervical canceroncogenicWnt/β-catenin[100]disrupts destruction complex via GSK3βbladder canceroncogenicWnt/β-catenin[102]miR-621 suppresses both TRIM29 and Wnt/β-cateninliver canceranti-cancersuppresses Wnt/β-catenin[182]?breast canceranti-cancersuppresses EMT[169]downregulates TWISTmammary epithelial cellsanti-cancersuppresses EMT[169] [173]downregulates TWISTesophageal canceranti-cancersuppresses STAT3 and EMT[179]promotes ZNF750 and suppresses SNAI1Oncogenic Functionspancreatic canceroncogenicstemness[111]suppresses CAPN3 to stimulate ISG15, thereby activating ERK1/2human umbilical cord-derived mesenchymal stem cellsoncogenicstemness[113]promotes pERK1/2ovarian canceroncogenicstemness[123]SETBP1/SET/PP2Apancreatic canceroncogenicmetabolism[127]stimulates AK4 to promote glycolysis and survivalcolorectal canceroncogenicmetabolism[133]improves glycolysislung canceroncogenicautophagy[137]promotes Beclin-1nasopharyngeal canceroncogenicmitophagy[125]binds and activates VDAC1breast canceranti-cancerhypoxic response[30]stimulated by ATM then suppresses TWISTOtherscolorectal canceroncogenic?[194]promotes degradation of KRT5Squamous cell carcinomaanti-cancerinterferes with metastatic behavior[137]keratin distributionthyroid canceroncogenic?[126]suppresses miR873-5p via CYTOR, thereby promoting FN1Fig. 6TRIM29 promotes carcinogenic activities. (FN1 = fibronectin1; AK4 = adenylate kinase isoform 4; PKM1 = pyruvate kinase M1; VDAC1 = voltage-dependent anion-selective channel 1; CAPN3 = calpain 3; ISG15 = interferon-stimulated gene 15; BICC1 = BicC family RNA binding protein 1; VEZF1 = vascular endothelial zinc finger 1; SETBP1 = SET binding protein 1; PP2A = protein phosphatase-2 A) Table 1TRIM29 and its association with various pathways in cancerContextRolePathwayCitationMechanismregulation of p53colorectal canceroncogenicp53[50, 59]sequesters p53 at cytosolcolorectal canceroncogenicp53[51]inhibits Tip60NF-κB signaling pathwaylung canceroncogenicNF-κB[65]?bladder canceroncogenicNF-κB[66]activates PKCPI3K/AKT/mTORthyroid canceroncogenicPI3K/AKT/mTOR[69]?colorectal canceroncogenicPI3K/AKT/mTOR[70]suppresses PHLPP1 via ubiquitinationnasopharyngeal canceroncogenicPI3K/AKT/mTOR[32]suppresses PTENnasopharyngeal canceroncogenicPI3K/AKT/mTOR[31]may have relation with miR-122bladder canceroncogenicPI3K/AKT/mTOR[41]by inducing MYC, DNMT3A activation leads to suppression of PTENoncogenic KRASpancreatic canceroncogeniconcogenic KRAS[79, 80]promotes PanIN and stimulates Wnt/β-cateninHIPPOpancreatic canceroncogenicHIPPO[106]inhibits ubiquitination of YAP1Wnt/β-catenin and EMTpancreatic canceroncogenicWnt/β-catenin[45]disrupts destruction complex via DVL2pancreatic canceroncogenicWnt/β-catenin[79]in the presence of oncogenic KRAS, stimulates Wnt/β-cateninpancreatic canceroncogenicWnt/β-catenin[96]miR-449a suppresses both TRIM29 and β-cateningastric canceroncogenicWnt/β-catenin[99]may have relation with miR-185cervical canceroncogenicWnt/β-catenin[100]disrupts destruction complex via GSK3βbladder canceroncogenicWnt/β-catenin[102]miR-621 suppresses both TRIM29 and Wnt/β-cateninliver canceranti-cancersuppresses Wnt/β-catenin[182]?breast canceranti-cancersuppresses EMT[169]downregulates TWISTmammary epithelial cellsanti-cancersuppresses EMT[169] [173]downregulates TWISTesophageal canceranti-cancersuppresses STAT3 and EMT[179]promotes ZNF750 and suppresses SNAI1Oncogenic Functionspancreatic canceroncogenicstemness[111]suppresses CAPN3 to stimulate ISG15, thereby activating ERK1/2human umbilical cord-derived mesenchymal stem cellsoncogenicstemness[113]promotes pERK1/2ovarian canceroncogenicstemness[123]SETBP1/SET/PP2Apancreatic canceroncogenicmetabolism[127]stimulates AK4 to promote glycolysis and survivalcolorectal canceroncogenicmetabolism[133]improves glycolysislung canceroncogenicautophagy[137]promotes Beclin-1nasopharyngeal canceroncogenicmitophagy[125]binds and activates VDAC1breast canceranti-cancerhypoxic response[30]stimulated by ATM then suppresses TWISTOtherscolorectal canceroncogenic?[194]promotes degradation of KRT5Squamous cell carcinomaanti-cancerinterferes with metastatic behavior[137]keratin distributionthyroid canceroncogenic?[126]suppresses miR873-5p via CYTOR, thereby promoting FN1 TRIM29 and its association with various pathways in cancer TRIM29 promotes carcinogenic activities. (FN1 = fibronectin1; AK4 = adenylate kinase isoform 4; PKM1 = pyruvate kinase M1; VDAC1 = voltage-dependent anion-selective channel 1; CAPN3 = calpain 3; ISG15 = interferon-stimulated gene 15; BICC1 = BicC family RNA binding protein 1; VEZF1 = vascular endothelial zinc finger 1; SETBP1 = SET binding protein 1; PP2A = protein phosphatase-2 A)